Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM).
Lapuente JP, Blázquez-Martínez A, Marco-Brualla J, Gómez G, Desportes P, Sanz J, Fernández P, García-Gil M, Bermejo F, San Martín JV, Algaba A, De Gregorio JC, Lapuente D, De Gregorio A, Lapuente B, Andrés MV, Anel A. Lapuente JP, et al. Among authors: garcia gil m. Biomolecules. 2022 Mar 31;12(4):534. doi: 10.3390/biom12040534. Biomolecules. 2022. PMID: 35454123 Free PMC article.
Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells).
Lapuente JP, Gómez G, Marco-Brualla J, Fernández P, Desportes P, Sanz J, García-Gil M, Bermejo F, San Martín JV, Algaba A, De Gregorio JC, Lapuente D, De Gregorio A, Lapuente B, Gómez S, Andrés MLV, Anel A. Lapuente JP, et al. Among authors: garcia gil m. Biomedicines. 2022 May 8;10(5):1094. doi: 10.3390/biomedicines10051094. Biomedicines. 2022. PMID: 35625831 Free PMC article.
Early clinical experience with imatinib in COVID-19: Searching for a dual effect.
Morales-Ortega A, Rivas-Prado L, Frutos-Pérez B, Jaenes-Barrios B, Farfán-Sedano AI, García-Parra CJ, Hernández-Muniesa B, Duarte-Millán MÁ, Madroñal-Cerezo E, Ontañón-Nasarre A, Ruiz-Giardín JM, Bermejo F, García-Gil M, Gonzalo-Pascua S, San Martín-López JV, Bernal-Bello D. Morales-Ortega A, et al. Among authors: garcia gil m. J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2021.02.002. Epub 2021 Feb 5. J Infect. 2021. PMID: 33549625 Free PMC article.
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial.
Morales-Ortega A, Farfán-Sedano AI, San Martín-López JV, Escribá-Bárcena A, Jaenes-Barrios B, Madroñal-Cerezo E, Llarena-Barroso C, Mesa-Plaza N, Frutos-Pérez B, Ruiz-Giardín JM, Duarte-Millán MÁ, Piedrabuena-García SI, Carpintero-García L, Canalejo-Castrillero E, Mora-Hernández B, García-Parra CJ, Magro-García HA, Algaba-García A, Hernández-Muniesa B, Nasarre-López B, Ontañón-Nasarre A, Domínguez-García MJ, Gómez-Santos D, Prieto-Menchero S, García de Tena J, Bermejo F, García-Gil M, Gonzalo-Pascua S, Bernal-Bello D; COVINIB Study Group investigators. Morales-Ortega A, et al. Among authors: garcia gil m. J Med Virol. 2023 Feb;95(2):e28495. doi: 10.1002/jmv.28495. J Med Virol. 2023. PMID: 36639911 Clinical Trial.
Imatinib might constitute a treatment option for lung involvement in COVID-19.
Bernal-Bello D, Jaenes-Barrios B, Morales-Ortega A, Ruiz-Giardin JM, García-Bermúdez V, Frutos-Pérez B, Farfán-Sedano AI, de Ancos-Aracil C, Bermejo F, García-Gil M, Zapatero-Gaviria A, San Martín-López JV. Bernal-Bello D, et al. Among authors: garcia gil m. Autoimmun Rev. 2020 Jul;19(7):102565. doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3. Autoimmun Rev. 2020. PMID: 32376403 Free PMC article. No abstract available.